Global law firm White & Case LLP successfully represented Anchorage Capital in getting a chapter 11 plan approved for the liquidation of Zais Investment Grade Limited VII, a Cayman Islands-based distressed CDO.

The Firm recently represented the underwriters, led by Citigroup, RBS, Barclays Capital, Goldman, Sachs & Co. and J.P. Morgan, in the public offering of $800 million of floating rate notes due 2013 of Kraft Foods Inc. (“Kraft”). The notes must be redeemed before Kraft spins off its North American grocery business.

Proskauer announced the expansion of its Antitrust Group with the addition of Helene D. Jaffe as a Partner in New York City and co-head of the practice.

New York, New York, January 9, 2012.  Morrison Cohen LLP announced today the admission to the firm of its newest lateral partner, Bruce P. Levine.

Perkins Coie is pleased to announce that Gary Eisenberg has joined the firm’s New York office as Partner in the firm’s Financial Transactions & Restructuring practice. He joins the firm from Herrick, Feinstein LLP.

Global law firm White & Case LLP today announced it is representing a group of bondholders, including institutional holders and secondary holders, with more than $800 million of secured bonds from Rescap.

Wragge & Co’s Life Sciences team has advised ProStrakan Group plc on a cross-border licensing and distribution agreement with international pharmaceutical company Aptalis Pharma Inc. The deal is Wragge & Co’s first major instruction from ProStrakan, the international specialty pharmaceutical company which is part of the Kyowa Hakko Kirin Co. Ltd. (KHK) group of companies.

Shearman & Sterling is representing B/E Aerospace in its acquisition of UFC Aerospace Corp. in a transaction valued at approximately $400 million. The acquisition is expected to close in the first quarter of 2012.

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex’s shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex’s common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

WilmerHale is pleased to announce that Richard Andersen and Lisa Firenze have joined the firm’s New York office as partners in the Transactional Department and members of the Tax Group and Corporate Group, respectively. With a combined 50 years of experience handling transactional matters for a variety of clients, their arrival denotes the firm’s commitment to the strategic expansion of its New York office.